ERBB2 and neoplasm: Molecular markers such as RAS (KRAS/NRAS) mutations, BRAF mutations, HER2 amplification, microsatellite instability (MSI) or mismatch repair (MMR) status, and tumor mutational burden (TMB) have become central to therapy selection and prognosis [105].